HIGH DENSITY LIPOPROTEIN CHOLESTEROL PROMOTES THE PROLIFERATION OF BONE-DERIVED MESENCHYMAL STEM CELLS VIA BINDING SCAVENGER RECEPTOR-B TYPE I AND ACTIVATION OF PI3K/AKT, MAPK/ERK PATHWAYS

doi:10.1136/heartjnl-2012-302920a.97

1Xu Jian-feng, 1Qian Ju-ying, 1Xie Xin-xing, 2Lin Li, 1Sun Ai-jun, 1Zou Yun-zeng, 1Ge Jun-bo, 1Qian Juying. 1Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 2Department of Cardiology, Eastern Hospital, Tongji University, Shanghai 200120, China

Objectives To investigate the effect of high density lipoprotein (HDL) on the proliferation of mesenchymal stem cells (MSCs), and to elucidate the molecular mechanisms involved.
Methods  MSCs derived from rats was treated with HDL in different concentration or for different periods. The proliferation of MSCs was measured with MTT and BrdU assay. The expressions of p21 and phosphorylation of Akt, ERK1/2 were evaluated by western blot. The activity of pathways was down-regulated by the respective specific inhibitor, and the gene of Scavenger Receptor-B Type I (SR-BI) was knocked down by RNA interference.

Results  We found that HDL promoted MSCs proliferation in a time- and concentration-dependent manner, in which the phosphorylation of Akt, ERK1/2 were up-regulated and the level of p21 was down-regulated. When MSCs was preconditioned with the specific inhibitor to respective pathways, the decrease of p21 induced by HDL was significantly attenuated compared with that without preconditioning (LY294002: 1.03±0.16 vs 0.69±0.13, p<0.05; U0126: 1.68±0.17 vs 0.76±0.15, p<0.05). SR-BI contributed to HDL-induced proliferation of MSCs, which was effectively abolished by the knock-down of SR-BI. Compared with respective PBS-treatment groups, MSCs transfected with mock siRNA displayed a higher BrdU incorporation rate after administration of HDL (0.98±0.16 vs 1.57±0.23, p<0.05), while the MSCs transfected with SR-BI siRNA showed no change (1.08±0.15 vs 1.08±0.14, p > 0.05).

Conclusions  HDL improves the proliferation of MSCs in a time- and concentration-dependent manner through PI3K/Akt and MAPK/ERK1/2 pathways and binding SR-BI receptor.